![](/fileadmin/_processed_/csm_NALFD_model_7770420204.png)
DefiniGEN and Atelerix prevent freezing damage in cell models
The agreement between the British companies combines DefiniGEN’s iPSC hepatocytes (Opti-Heps) with Atelerix's hydrogel preservation technology, which...
![](/fileadmin/_processed_/csm_HIV__63e20764dc.jpg)
Naobios and Sumagen partner to develop HIV vaccine
Under the contract, Naobios SAS will provide bioprocess development and GMP production of clinical batches of a virus-based HIV vaccine candidate...
![](/fileadmin/_processed_/csm_CordenPharma-Peptide-Expansion-Press-Release-16-July-2024-for-Web-1-1024x614_520d0c7270.jpg)
CordenPharma invests €900m in peptide patform expansion
CordenPharma has announced its largest strategic investment to date with a committed spend of ~€900m over the next 3 years to grow its peptide...
![](/fileadmin/_processed_/csm_drugs_pills_-web_4e35a70ff4.jpg)
Ten drug recommendations by EMA
The committee recommended end of June granting a marketing authorisation for Balversa (erdafitinib), for the treatment of adult...
![](/fileadmin/_processed_/csm_anacura_griet_ohmxbio_104d007f0f.jpg)
Anacura aquires Ohmx.bio
Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a also...
![](/fileadmin/_processed_/csm_Evotec_HQ_516a5db450.jpg)
Consortium led by Evotec enters obesity drug space
The newly formed strategic partnership between Evotec SE, Inserm, Lille University Hospital and Inserm Transfert aims to identify novel multimodal...
![](/fileadmin/Content/NewsAndStories/2024/National_Eye_Institute.png)
Seabelife SAS to develop next-gen dry AMD drug
French drug developer SeaBeLife SAS has bagged a €1.5m fund within the i-Nov 2024 innovation competition, which is part of the French government’s...